FPA144

FGFR2b-targeted monoclonal antibody · Five Prime Therapeutics

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for FPA144, covering 2020-03-11 to 2020-03-11. Get the full timeline:

Most recent: Clinical Trial Update: Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors [Phase 1]

See pricing